MX339619B - Formulaciones, sales y polimorfos de transnorsertralina y usos de los mismos. - Google Patents

Formulaciones, sales y polimorfos de transnorsertralina y usos de los mismos.

Info

Publication number
MX339619B
MX339619B MX2012006226A MX2012006226A MX339619B MX 339619 B MX339619 B MX 339619B MX 2012006226 A MX2012006226 A MX 2012006226A MX 2012006226 A MX2012006226 A MX 2012006226A MX 339619 B MX339619 B MX 339619B
Authority
MX
Mexico
Prior art keywords
transnorsertraline
salts
polymorphs
formulations
methods
Prior art date
Application number
MX2012006226A
Other languages
English (en)
Spanish (es)
Other versions
MX2012006226A (es
Inventor
m laughlin Sharon
P Singh Surendra
J Sizensky Michael
h wilkinson Scott
Gu Huang Cai
James Bonasia Philip
S D'souza Susan
Original Assignee
Sunovion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunovion Pharmaceuticals Inc filed Critical Sunovion Pharmaceuticals Inc
Publication of MX2012006226A publication Critical patent/MX2012006226A/es
Publication of MX339619B publication Critical patent/MX339619B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/33—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C211/39—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton
    • C07C211/41—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems
    • C07C211/42—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to carbon atoms of rings other than six-membered aromatic rings of an unsaturated carbon skeleton containing condensed ring systems with six-membered aromatic rings being part of the condensed ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
MX2012006226A 2009-12-04 2010-12-03 Formulaciones, sales y polimorfos de transnorsertralina y usos de los mismos. MX339619B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26686409P 2009-12-04 2009-12-04
PCT/US2010/058831 WO2011069032A2 (fr) 2009-12-04 2010-12-03 Formulations, sels et polymorphes de la transnorsertraline, et leurs utilisations

Publications (2)

Publication Number Publication Date
MX2012006226A MX2012006226A (es) 2012-06-19
MX339619B true MX339619B (es) 2016-06-02

Family

ID=44115510

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016006875A MX367327B (es) 2009-12-04 2010-12-03 Formulaciones, sales y polimorfos de transnorsertralina y usos de los mismos.
MX2012006226A MX339619B (es) 2009-12-04 2010-12-03 Formulaciones, sales y polimorfos de transnorsertralina y usos de los mismos.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2016006875A MX367327B (es) 2009-12-04 2010-12-03 Formulaciones, sales y polimorfos de transnorsertralina y usos de los mismos.

Country Status (20)

Country Link
US (3) US8957114B2 (fr)
EP (2) EP2937083B1 (fr)
JP (2) JP5766713B2 (fr)
KR (1) KR101755743B1 (fr)
CN (2) CN105125528A (fr)
AU (2) AU2010325894B2 (fr)
BR (1) BR112012013325B8 (fr)
CA (1) CA2782240A1 (fr)
DK (1) DK2506842T3 (fr)
ES (1) ES2531312T3 (fr)
HK (2) HK1175692A1 (fr)
IL (2) IL219963A (fr)
MX (2) MX367327B (fr)
NZ (1) NZ600107A (fr)
PL (1) PL2506842T3 (fr)
PT (1) PT2506842E (fr)
RU (2) RU2016104396A (fr)
SG (1) SG181466A1 (fr)
WO (1) WO2011069032A2 (fr)
ZA (1) ZA201203621B (fr)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8134029B2 (en) 2002-09-16 2012-03-13 Sunovion Pharmaceuticals Inc. Treatment of CNS disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine
JP2009500425A (ja) 2005-07-06 2009-01-08 セプラコア インコーポレーテッド エスゾピクロン及びトランス４−（３，４−ジクロロフェニル）−１，２，３，４−テトラヒドロ−ｎ−メチル−１−ナフタレンアミン又はトランス４−（３，４−ジクロロフェニル）−１，２，３，４−テトラヒドロ−１−ナフタレンアミンの組み合わせ、並びに閉経期並びに気分、不安、及び認知障害の治療方法
JP6226471B2 (ja) * 2014-02-12 2017-11-08 株式会社リガク 構造精密化装置、方法およびプログラム
WO2015175514A1 (fr) * 2014-05-13 2015-11-19 Sunovion Pharmaceuticals Inc. Méthodes et compositions de dasotraline pour le traitement du thada
WO2015175523A1 (fr) * 2014-05-13 2015-11-19 Sunovion Pharmaceuticals Inc. Dosage de dasotraline et méthode pour le traitement du tdah
WO2019143920A1 (fr) * 2018-01-19 2019-07-25 Sunovion Pharmaceuticals Inc. Formes posologiques orales
CN110310711B (zh) * 2019-06-26 2023-06-27 河南省人造金刚石微粉质量监督检验中心 一种金刚石微粉杂质含量分析结果的不确定度评定方法

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5213738A (en) 1990-05-15 1993-05-25 L. Perrigo Company Method for making a capsule-shaped tablet
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
EP1239839A2 (fr) * 1999-12-23 2002-09-18 Pfizer Products Inc. Forme de dosage d'un medicament stratifie entraine par un hydrogel
US20060057207A1 (en) * 2001-11-30 2006-03-16 Pfizer Inc Fast-disintegrating dosage forms of 5,8,14-triazatetracyclo[10.3.1.02,11.04,9]-hexadeca-2(11),3,5,7,9-pentaene
US7087785B2 (en) * 2002-09-16 2006-08-08 Sepracor Inc. Treatment of CNS disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine and its formamide
CN100584818C (zh) * 2002-09-16 2010-01-27 塞普拉科公司 用反式4-(3,4-二氯苯基)-1,2,3,4-四氢-1-萘胺及其甲酰胺治疗cns病症
JP2006504693A (ja) 2002-09-16 2006-02-09 セプラコア インコーポレーテッド トランス４−（３，４−ジクロロフェニル）−１，２，３，４−テトラヒドロ−ｎ−メチル−１−ナフタレンアミンによるｃｎｓ障害の治療
JP2009500425A (ja) 2005-07-06 2009-01-08 セプラコア インコーポレーテッド エスゾピクロン及びトランス４−（３，４−ジクロロフェニル）−１，２，３，４−テトラヒドロ−ｎ−メチル−１−ナフタレンアミン又はトランス４−（３，４−ジクロロフェニル）−１，２，３，４−テトラヒドロ−１−ナフタレンアミンの組み合わせ、並びに閉経期並びに気分、不安、及び認知障害の治療方法
DK2013835T3 (en) * 2006-03-31 2015-12-14 Sunovion Pharmaceuticals Inc Preparation of chiral amides and AMINES
KR20090015089A (ko) * 2006-05-31 2009-02-11 세프라코 아이엔시. 트랜스 4-(3,4-디클로로페닐)-1,2,3,4-테트라하이드로-1-나프탈렌아민 및 그의 포름아미드에 의한 통증장애 치료방법
US7711807B2 (en) * 2006-07-27 2010-05-04 Intel Corporation Selective filtering of exception data units
US20060257475A1 (en) * 2006-08-17 2006-11-16 Boehringer Ingelheim International Gmbh Stable Sertraline Hydrochloride Formulation and Method
US20120077818A1 (en) * 2009-05-13 2012-03-29 Sunovion Pharmaceuticals Inc. Compositions comprising transnorsertraline and serotonin receptor 1a agonists/antagonists and uses thereof

Also Published As

Publication number Publication date
PT2506842E (pt) 2015-03-10
AU2010325894A1 (en) 2012-06-07
EP2506842B1 (fr) 2015-01-21
BR112012013325B1 (pt) 2021-05-18
MX367327B (es) 2019-08-15
JP2013512921A (ja) 2013-04-18
PL2506842T3 (pl) 2015-06-30
AU2015249065A1 (en) 2015-11-12
US20130116332A1 (en) 2013-05-09
NZ600107A (en) 2014-10-31
SG181466A1 (en) 2012-07-30
EP2506842A4 (fr) 2013-05-22
JP5766713B2 (ja) 2015-08-19
RU2012127777A (ru) 2014-01-20
CN105125528A (zh) 2015-12-09
WO2011069032A2 (fr) 2011-06-09
HK1216986A1 (zh) 2016-12-16
CN102740842A (zh) 2012-10-17
EP2937083A1 (fr) 2015-10-28
RU2016104396A (ru) 2018-11-23
RU2578956C2 (ru) 2016-03-27
IL248077A0 (en) 2016-11-30
CA2782240A1 (fr) 2011-06-09
CN102740842B (zh) 2015-07-01
US20150196502A1 (en) 2015-07-16
KR20120089362A (ko) 2012-08-09
BR112012013325A2 (pt) 2017-09-05
DK2506842T3 (en) 2015-02-23
MX2012006226A (es) 2012-06-19
HK1175692A1 (zh) 2013-07-12
ZA201203621B (en) 2013-08-28
AU2010325894B2 (en) 2015-07-30
BR112012013325B8 (pt) 2021-05-25
JP2015199763A (ja) 2015-11-12
EP2937083B1 (fr) 2019-03-27
US8957114B2 (en) 2015-02-17
IL219963A (en) 2017-01-31
ES2531312T3 (es) 2015-03-12
WO2011069032A3 (fr) 2011-10-27
US20180071230A1 (en) 2018-03-15
IL248077B (en) 2020-05-31
AU2015249065B2 (en) 2017-07-20
EP2506842A2 (fr) 2012-10-10
KR101755743B1 (ko) 2017-07-07
IL219963A0 (en) 2012-07-31

Similar Documents

Publication Publication Date Title
MX2012001974A (es) Compuestos de biarilo y metodos de uso de los mismos.
MX2020001602A (es) Inhibidor del antigeno-1 asociado a la funcion del linfocito (lfa-1) y polimorfo del mismo.
IL214396A (en) Anti-viral anti-viral nucleosides, pharmaceutical preparations containing them and methods for their preparation, as well as their preparation of antiviral intermediates
UA102251C2 (ru) Производные аминодигидротиазина как ингибиторы васе для лечения болезни альцгеймера
MX2020012825A (es) Compuestos multiciclicos y metodos de uso de los mismos.
HK1163500A1 (en) Pharmaceutical composition for the treatment of heart diseases
GEP20094784B (en) Sustained release pharmaceutical formulations
MX341197B (es) Compuestos de isoindol 5 - sustituidos.
WO2013072932A3 (fr) Compositions de soin oral
CR20200220A (es) FORMAS SÓLIDAS DE ÁCIDO {[5-(3-CLOROFENIL)-3-HIDROXIPIRIDIN-2-CARBONIL]AMINO}ACÉTICO, COMPOSICIONES, Y USOS DE LAS MISMAS (Divisional 2016-0222)
MX2011003473A (es) Composiciones para el cuidado bucal.
IN2012DN03182A (fr)
TN2011000647A1 (en) Fused imidazoles and compositions comprising them for the treatment of parasitic diseases such as e.g. malaria
IL208357A0 (en) Spiro-indole derivatives for the treatment of parasitic diseases
MX2012001660A (es) Formulaciones que contienen linaclotida para adminstracion oral.
MX367327B (es) Formulaciones, sales y polimorfos de transnorsertralina y usos de los mismos.
IN2014CN03597A (fr)
WO2011150201A3 (fr) Composés azolylamide et leurs procédés d'utilisation
PH12017500089A1 (en) Aldosterone synthase inhibitors
PL2502635T3 (pl) Połączone preparaty do leczenia męskiej niepłodności
IN2013DN02555A (fr)
EP2528440A4 (fr) Norindénoisoquinoléines substituées, leurs synthèses et leurs procédés d'utilisation
MX2010004620A (es) Derivados de benzomorfolina y metodos de uso.
MX2010003056A (es) Polimorfos de valomaciclovir.
TN2010000488A1 (en) Aminodihydrothiazine derivatives as bace inhibitors for the treatment of alzheimer's disease

Legal Events

Date Code Title Description
FG Grant or registration